Literature DB >> 16648113

Molecular biology in prostate cancer.

José Ramón Cansino Alcaide1, Luis Martínez-Piñeiro.   

Abstract

Genes involved in cancer generation are usually tumor suppressors and oncogenes. Progressive genetic alterations in these genes are involved in the mechanisms of tumorigenesis. In prostate cancer, additionally several chromosomal loci that should harbor mutated genes have been proposed. Some genes have been found altered in prostate cancer, such as PTEN, TP53, AR, RNASEL (HPC1), ELAC2 (HPC2), CDKN2A and MSR1 and those can be natural targets for new strategies of treatment. Besides, gene therapy has been suggested to be suitable for prostate cancer treatment. This approach includes ex vivo corrective therapy, suicide, and antisense therapy.

Entities:  

Mesh：

Year:  2006        PMID： 16648113     DOI： 10.1007/s12094-006-0004-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  28 in total

1.  p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.

Authors:  D Theodorescu; S R Broder; J C Boyd; S E Mills; H F Frierson
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

2.  High-grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer.

Authors:  A Alcaraz; M A Barranco; J M Corral; M J Ribal; A Carrió; C Mallofré; J Llopis; A Cetina; R Alvarez-Vijande
Journal:  Prostate       Date:  2001-04       Impact factor: 4.104

3.  Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.

Authors:  N M Makridakis; R K Ross; M C Pike; L E Crocitto; L N Kolonel; C L Pearce; B E Henderson; J K Reichardt
Journal:  Lancet       Date:  1999-09-18       Impact factor: 79.321

4.  V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.

Authors:  R K Nam; A Toi; D Vesprini; M Ho; W Chu; S Harvie; J Sweet; J Trachtenberg; M A Jewett; S A Narod
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

5.  Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer.

Authors:  O Saramäki; N Willi; O Bratt; T C Gasser; P Koivisto; N N Nupponen; L Bubendorf; T Visakorpi
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

6.  Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.

Authors:  R E Reiter; I Sato; G Thomas; J Qian; Z Gu; T Watabe; M Loda; R B Jenkins
Journal:  Genes Chromosomes Cancer       Date:  2000-01       Impact factor: 5.006

7.  Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer.

Authors:  P Stattin; J E Damber; L Karlberg; A Bergh
Journal:  J Urol       Date:  1997-01       Impact factor: 7.450

8.  BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.

Authors:  D S Scherr; E D Vaughan; J Wei; M Chung; D Felsen; R Allbright; B S Knudsen
Journal:  J Urol       Date:  1999-07       Impact factor: 7.450

9.  Gene therapy for cancer using tumour-specific prodrug activation.

Authors:  J D Harris; A A Gutierrez; H C Hurst; K Sikora; N R Lemoine
Journal:  Gene Ther       Date:  1994-05       Impact factor: 5.250

10.  Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer.

Authors:  A Alcaraz; S Takahashi; J A Brown; J F Herath; E J Bergstralh; J J Larson-Keller; M M Lieber; R B Jenkins
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701
View more
  5 in total

Review 1.  Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer.

Authors:  A Valentino; P Reclusa; R Sirera; M Giallombardo; C Camps; P Pauwels; S Crispi; C Rolfo
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

2.  Heat shock protein 90 stabilizes nucleolin to increase mRNA stability in mitosis.

Authors:  Shao-An Wang; Hao-Yi Li; Tsung-I Hsu; Shu-Hui Chen; Chin-Jen Wu; Wen-Chang Chang; Jan-Jong Hung
Journal:  J Biol Chem       Date:  2011-10-13       Impact factor: 5.157

3.  The current state of preclinical prostate cancer animal models.

Authors:  Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

4.  The evolving biology and treatment of prostate cancer.

Authors:  Russel S Taichman; Robert D Loberg; Rohit Mehra; Kenneth J Pienta
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

5.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.